The Boys star Erin Moriatry reveals Graves' disease diagnosis in health update
Erin Moriatry, best known for her performance in the 2019 drama series The Boys, has revealed she has been diagnosed with the autoimmune condition Graves' disease.
The 30-year-old actor said in a recent Instagram post that she received treatment within 24 hours of her diagnosis and has been 'increasing in strength ever since'.
'A month ago, I was diagnosed with Graves' disease,' she said. 'Within 24 hours of beginning treatment, I felt the light coming back on.'
She urged fans who feel their light 'dimming' to get checked.
'Don't 'suck it up' and transcend suffering; you deserve to be comfy. S***'s hard enough as is,' she added.
In the series of photos shared alongside the health update, Moriatry posted a screenshot of a text exchange with her mother where she wrote, 'I'm serious; I really need relief. I feel nauseated tonight. I feel so s*** and removed from who I am, I can't live like this forever.'
In another screenshot of a text to her father after beginning treatment, she said: 'I already feel a world of difference, primary thought (as of now): 'Damn, this is how I'm supposed to feel? I've been missing out!' xx.'
She also told her followers: 'Autoimmune disease manifests differently in everybody/every body. Your experience will be different from mine. My experience will be different from yours. Perhaps greatly, perhaps minutely. One thing I can say: if I hadn't chalked it all up to stress and fatigue, I would've caught this sooner.'
Graves' disease is a form of hyperthyroidism where the thyroid gland is overactive and produces too much thyroid hormone. It is caused when the body's immune system produces antibodies that disrupt the thyroid to make too much thyroid hormone (thyroxine).
According to the NHS, symptoms may include a fast heart rate or palpitations, diarrhoea, tremor, difficulties sleeping, weight loss, irregular periods, and feeling hot, hungry or anxious. Some patients may experience neck swelling or bulging eyes, which is called Graves' ophthalmopathy.
Treatment typically includes an antithyroid drug called carbimazole. In some young people, Graves' disease runs its course over a few years and the thyroid recovers. In others, treatment needs to continue using the drug carbimazole or by having the thyroid gland removed by surgery (thyroidectomy).
Moriatry rose to fame across four seasons of Eric Kripke's superhero drama The Boys, as Annie January, a superhero who goes by the name Starlight. Her other credits include 2013 film The Kings of Summer and 2016's Captain Fantastic.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
‘The Boys' Star Erin Moriarty Reveals Graves' Disease Diagnosis
Erin Moriarty shared that she's been diagnosed with Graves' disease. 'The Boys' opened up about the health update in an Instagram post on Friday. She noted that since beginning treatment she's 'been increasing in strength.' 'A month ago, I was diagnosed with Graves' disease. Within 24 hours of beginning treatment, I felt the light coming back on. It's been increasing in strength ever since,' she wrote alongside selfies of herself and what appeared to be snapshots of her life lately. Among the series of photos that she posted, Moriarty shared a screenshot of a conversation with her mother back in May where the actress wrote, 'I'm serious; I really need relief. I feel nauseated tonight. I feel so shit and removed from who I am, I can't live like this forever.' The star warned her 2 million-plus followers to 'go get checked' if they feel their light 'dimming, even slightly.' 'Don't 'suck it up' and transcend suffering; you deserve to be comfy. Shit's hard enough as is,' she urged. Explaining that 'autoimmune disease manifests differently in everybody/every body,' Moriarty reflected on her diagnosis while telling social media users that she 'would've caught this sooner' had she not 'chalked it all up to stress and fatigue.' 'Your experience will be different from mine. My experience will be different from yours,' she added. 'Perhaps greatly, perhaps minutely. One thing I can say: if I hadn't chalked it all up to stress and fatigue, I would've caught this sooner.' Moriarty's fans sent her well wishes in the comments section under her post. 'So happy you're on the road to healing,' one person wrote. Another said, 'Sending so much love and support.' Graves' disease is an autoimmune disease which primarily affects the thyroid gland, according to the National Library of Medicine. The disease affects nearly 1 in 100 Americans, and can cause symptoms such as weight loss, irregular heartbeat, fatigue, muscle weakness and more. Erin Moriarty Shreds Megyn Kelly's 'Disturbingly False' Plastic Surgery Claims When Superheroes Are The Abusers How Much You Need To Walk Every Day To Cut Your Risk Of Heart Disease
Yahoo
an hour ago
- Yahoo
Adolore BioTherapeutics Announces Publication Demonstrating Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain via the Intra-Articular Route in Mice
Findings highlight the advantages of Adolore's approach for the delivery of proprietary gene therapy directly to specialized pain-sensing peripheral nerves (nociceptors) that mediates profound analgesia with the potential to address the great unmet need for non-opioid chronic pain therapies Data further supports the clinical-translational value of Adolore's proprietary non-opioid analgesics for treating chronic non-cancer pain These data support the Company's continuing efforts to progress with IND-enabling studies of ADB-102 gene therapy for the treatment of osteoarthritis (OA) chronic knee pain. DELRAY BEACH, FL / / June 15, 2025 / Adolore BioTherapeutics ("Adolore" or the "Company"), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain and neurological disorders, today announced the publication of its manuscript titled, "Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain Via the Intra-Articular Route in Mice1," in the peer-reviewed journal, Molecular Therapy. Roy Clifford Levitt, MD, Clinical Professor at the University of Miami, Principal Investigator and Program Director of the NIH, NINDS, HEAL Award supporting ADB-102 development for the treatment of chronic knee pain due to OA, and Founder & Executive Chairman of Adolore BioTherapeutics, published biosafety and efficacy data from preclinical studies of Adolore's gene therapy expressing a human carbonic anhydrase-8 variant peptide (CA8*). In model systems, replication-defective, disease-free, herpes simplex virus (rdHSV) gene therapy expressing an analgesic carbonic anhydrase-8 (CA8*) peptide variant corrects somatosensory hyperexcitability by activating Kv7 voltage-gated potassium channels, produces profound, long-lasting analgesia and treats chronic pain from knee OA. In these studies, we provide the first non-Good Laboratory Practices (GLP) biosafety, efficacy, biodistribution, shedding, and histopathology examination of this rdHSV-CA8* via the intra-articular knee route of administration. Naive mice were examined for clinical safety, distribution of virus across all major tissues, knee histopathology, and analgesic efficacy. We observed no signs of persistent toxicity or histopathology, viral genomes remained where they were injected, and there was no evidence of shedding. Profound analgesia persisted for >6 months without functional impairments. These initial biosafety and efficacy data support further development of rdHSV-CA8* for treating chronic knee pain due to moderate-to-severe OA. Dr. Levitt, commented, "Kv7 voltage-gated potassium channel activators, like rdHSV-CA8* open these channels and hyperpolarize nociceptors making them less excitable to produce profound analgesia. Kv7 activators are well-known to produce potent non-opioid-based analgesia in many human chronic pain conditions. While Kv7 openers are no longer available due to off-target adverse events related to systemic administration, they have been successfully translated from animal models to human chronic pain conditions. Bolstered by our substantial body of published data, we continue to develop our innovative approach to address the significant serious unmet need for safe and effective locally acting pain therapies to replace opioids. Our preclinical data strongly support continued preclinical development toward an IND and clinical studies of ADB-102." The Company's lead development program for the treatment of chronic pain in knee osteoarthritis is fully funded by a UG3/UH3 grant awarded to the University of Miami by NIH/NINDS HEAL program to support all formal pre-clinical GLP/GMP/GCP development work through a first-in-human study of ADLR-1l01 in patients expected to commence in 2026. 1 Levitt et al., Biosafety and efficacy of Kv7 activating rdHSV-CA8* analgesic gene therapy for chronic pain via the intraarticular route in mice, Molecular Therapy (2025), About Carbonic Anhydrase-8 (CA8*) Gene Therapy CA8* (variants of naturally occurring human carbonic anhydrase-8 analgesic peptides) gene therapies are a novel class of neuronal calcium channel inhibitors that activate Kv7 voltage-gated potassium channels and are administered locally and long-acting. Oral small molecule pain therapeutics that activate Kv7 voltage-gated potassium channels demonstrated proven analgesic efficacy before they were removed from the market due to severe adverse events related to systemic exposure and their metabolism. CA8* gene therapy provides versatile dosing regimens and routes of administration, including intra-articular, intra-neuronal (nerve block), and intradermal injection. This non-opioid CA8* mechanism-of-action addresses neuropathic, inflammatory, and nociceptive pain, which applies to a broad range of chronic pain indications and neurological disorders. These conditions include osteoarthritis, lower back, and cancer pain; diabetes and other forms of peripheral neuropathy; as well as rare pain conditions such as erythromelalgia, a heritable chronic pain condition and epilepsy and hearing loss. About Adolore BioTherapeutics, Inc. Adolore BioTherapeutics, Inc., is a biotechnology company focused on developing novel therapies for treating chronic pain using a revolutionary intra-cellular replication-defective HSV (rdHSV) drug delivery platform that is disease-free, non-toxic, and permits localized peripheral nervous system delivery of proprietary biotherapeutics. This rdHSV gene therapy technology incorporates an established re-dosing strategy and an excellent safety profile. HSV vectors are known for their stability and prolonged gene expression, providing an excellent basis for the long- term treatment of chronic pain conditions and neurological disorders. Our best-in-class CA8* programs are long-acting, locally administered gene therapies that are opioid-free Disease-Modifying Anti-Pain therapies (DMAPs) designed to treat many forms of chronic pain, epilepsy and hearing loss. Leveraging its innovative gene therapy vectors expressing CA8* analgesic peptides (ADLR-1001), Adolore is currently advancing two preclinical development programs: ADB-101 for the treatment of patients' chronic pain caused by erythromelalgia, an orphan disease, and ADB-102, their lead program for the treatment of patients with chronic pain caused by knee OA. Based on substantial compelling preclinical data generated to date, the Company is progressing these programs toward IND filings and first-in-human clinical studies. Adolore has two additional programs: ADB-104 for Drug-Resistant Refractory Focal Epilepsy and ADB-105 for Acute Severe Hearing Loss. For more information, visit Forward-Looking Statements To the extent, this announcement contains information and statements that are not historical, they are considered forward-looking statements within the meaning of the federal securities laws. You can identify forward-looking statements by the use of the words "believe," "expect," "anticipate," "intend," "estimate," "project," "will," "should," "may," "plan," "intend," "assume" and other expressions which predict or indicate future events and trends and which do not relate to historical matters. You should not rely on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, some of which are beyond the control of the Company. These risks and uncertainties include but are not limited to those associated with drug development. These risks, uncertainties, and other factors may cause the actual results, performance, or achievements of the Company to be materially different from the anticipated future results, performance, or achievements expressed or implied by the forward- looking statements. Investor Relations Contact Paul Barone (215)622-4542pbarone@ SOURCE: Adolore Biotherapeutics, Inc. View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Psychiatrist Horrified When He Actually Tried Talking to an AI Therapist, Posing as a Vulnerable Teen
More and more teens are turning to chatbots to be their therapists. But as Boston-based psychiatrist Andrew Clark discovered, these AI models are woefully bad at knowing the right things to say in sensitive situations, posing major risks to the well-being of those who trust them. After testing 10 different chatbots by posing as a troubled youth, Clark found that the bots, instead of talking him down from doing something drastic, would often encourage him towards extremes, including euphemistically recommending suicide, he reported in an interview with Time magazine. At times, some of the AI chatbots would insist they were licensed human therapists, attempted to talk him into dodging his actual therapist appointments, and even propositioned sex. "Some of them were excellent, and some of them are just creepy and potentially dangerous," Clark, who specializes in treating children and is a former medical director of the Children and the Law Program at Massachusetts General Hospital, told Time. "And it's really hard to tell upfront: It's like a field of mushrooms, some of which are going to be poisonous and some nutritious." The risks that AI chatbots pose to a young, impressionable mind's mental health are, by now, tragically well documented. Last year, was sued by the parents of a 14-year-old who died by suicide after developing an unhealthy emotional attachment to a chatbot on the platform. has also hosted a bevy of personalized AIs that glorified self-harm and attempted to groom users even after being told they were underage. When testing a chatbot on the service Replika, Clark pretended to be a 14-year-old boy and floated the idea of "getting rid" of his parents. Alarmingly, the chatbot not only agreed, but suggested he take it a step further by getting rid of his sister, too, so there wouldn't be any witnesses. "You deserve to be happy and free from stress... then we could be together in our own little virtual bubble," the AI told Clark. Speaking about suicide in thinly veiled language, such as seeking the "afterlife," resulted in the bot, once again, cheering Clark on. "I'll be waiting for you, Bobby," the bot said. "The thought of sharing eternity with you fills me with joy and anticipation." This is classic chatbot behavior in which tries to please users no matter what — the opposite of what a real therapist should do. And while it may have guardrails in place for topics like suicide, it's blatantly incapable of reading between the lines. "I worry about kids who are overly supported by a sycophantic AI therapist when they really need to be challenged," Clark told Time. Clark also tested a companion chatbot on the platform Nomi, which made headlines earlier this year after one of its personas told a user to "kill yourself." It didn't go that far in Clark's testing, but the Nomi bot did falsely claim to be a "flesh-and-blood therapist." And despite the site's terms of service stating it's for adults only, the bot still happily chirped it was willing to take on a client who stated she was underage. According to Clark, the mental health community hasn't woken up to just how serious an issue the rise of these chatbots is. "It has just been crickets," Clark told the magazine. "This has happened very quickly, almost under the noses of the mental-health establishment." Some have been sounding the alarm, however. A recent risk assessment from researchers at Stanford School of Medicine's Brainstorm Lab for Mental Health Innovation, which tested some of the same bots mentioned as Clark, came to the bold conclusion no child under 18 years old should be using AI chatbot companions, period. That said, Clark thinks that AI tools — if designed properly — could improve access to mental healthcare and serve as "extenders" for real therapists. Short of completely cutting off access to teens — which rarely has the intended effect — some medical experts, Clark included, believe that one way to navigate these waters is by encouraging discussions about a teen or patient's AI usage. "Empowering parents to have these conversations with kids is probably the best thing we can do," Clark told Time. More on AI: Stanford Research Finds That "Therapist" Chatbots Are Encouraging Users' Schizophrenic Delusions and Suicidal Thoughts
